Is This Blue-Chip Dividend Stock a Buy?
Numerous worries about the state of the global economy and geopolitical climate have led the S&P 500 index to dip 18% so far this year.
But not all stocks have fared poorly in 2022. In particular, healthcare stocks have held up quite well so far. And shares of one of the most dominant pharmaceutical stocks, Bristol Myers Squibb (NYSE: BMY), have soared 29% higher in 2022.
After such a run, is the stock a buy for dividend growth investors? Let's dive into Bristol Myers' fundamentals and valuation to address this question.
Source Fool.com